Standardised shorter regimens individualised longer regimens for rifampin- or multidrug-resistant tuberculosis.
Authors
Abidi, SAchar, J
Neino, MMA
Bang, D
Benedetti, A
Brode, S
Campbell, JR
Casas, EC
Conradie, F
Dravniece, G
du Cros, P
Falzon, D
Jaramillo, E
Kuaban, C
Lan, Z
Lange, C
Li, PZ
Makhmudova, M
Maug, AKJ
Menzies, D
Migliori, GB
Miller, A
Myrzaliev, B
Ndjeka, N
Noeske, J
Parpieva, N
Piubello, A
Schwoebel, V
Welile, S
Singla, R
Souleymane, MB
Trebucq, V
Van Deun, A
Viney, K
Weyer, K
Zhang, BJ
Khan, FA
Issue Date
2020-03-20Submitted date
2021-02-22
Metadata
Show full item recordJournal
The European Respiratory JournalAbstract
We sought to compare the effectiveness of two World Health Organization (WHO)-recommended regimens for the treatment of rifampin- or multidrug-resistant (RR/MDR) tuberculosis (TB): a standardised regimen of 9-12 months (the "shorter regimen") and individualised regimens of ≥20 months ("longer regimens"). We collected individual patient data from observational studies identified through systematic reviews and a public call for data. We included patients meeting WHO eligibility criteria for the shorter regimen: not previously treated with second-line drugs, and with fluoroquinolone- and second-line injectable agent-susceptible RR/MDR-TB. We used propensity score matched, mixed effects meta-regression to calculate adjusted odds ratios and adjusted risk differences (aRDs) for failure or relapse, death within 12 months of treatment initiation and loss to follow-up.We included 2625 out of 3378 (77.7%) individuals from nine studies of shorter regimens and 2717 out of 13 104 (20.7%) individuals from 53 studies of longer regimens. Treatment success was higher with the shorter regimen than with longer regimens (pooled proportions 80.0% versus 75.3%), due to less loss to follow-up with the former (aRD -0.15, 95% CI -0.17- -0.12). The risk difference for failure or relapse was slightly higher with the shorter regimen overall (aRD 0.02, 95% CI 0-0.05) and greater in magnitude with baseline resistance to pyrazinamide (aRD 0.12, 95% CI 0.07-0.16), prothionamide/ethionamide (aRD 0.07, 95% CI -0.01-0.16) or ethambutol (aRD 0.09, 95% CI 0.04-0.13).In patients meeting WHO criteria for its use, the standardised shorter regimen was associated with substantially less loss to follow-up during treatment compared with individualised longer regimens and with more failure or relapse in the presence of resistance to component medications. Our findings support the need to improve access to reliable drug susceptibility testing.Publisher
European Respiratory SocietyPubMed ID
31862767Type
ArticleOther
Language
enEISSN
1399-3003ae974a485f413a2113503eed53cd6c53
10.1183/13993003.01467-2019
Scopus Count
Collections
Related articles
- Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.
- Authors: Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien JY, Cox H, Dedicoat M, Erkens C, Escalante P, Falzon D, Garcia-Prats AJ, Gegia M, Gillespie SH, Glynn JR, Goldberg S, Griffith D, Jacobson KR, Johnston JC, Jones-López EC, Khan A, Koh WJ, Kritski A, Lan ZY, Lee JH, Li PZ, Maciel EL, Galliez RM, Merle CSC, Munang M, Narendran G, Nguyen VN, Nunn A, Ohkado A, Park JS, Phillips PPJ, Ponnuraja C, Reves R, Romanowski K, Seung K, Schaaf HS, Skrahina A, Soolingen DV, Tabarsi P, Trajman A, Trieu L, Banurekha VV, Viiklepp P, Wang JY, Yoshiyama T, Menzies D
- Issue date: 2018 Apr
- Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses.
- Authors: Ahmad Khan F, Salim MAH, du Cros P, Casas EC, Khamraev A, Sikhondze W, Benedetti A, Bastos M, Lan Z, Jaramillo E, Falzon D, Menzies D
- Issue date: 2017 Jul
- Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
- Authors: Grace AG, Mittal A, Jain S, Tripathy JP, Satyanarayana S, Tharyan P, Kirubakaran R
- Issue date: 2019 Dec 12
- Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan.
- Authors: du Cros P, Khamraev A, Tigay Z, Abdrasuliev T, Greig J, Cooke G, Herboczek K, Pylypenko T, Berry C, Ronnachit A, Lister D, Dietrich S, Ariti C, Safaev K, Nyang'wa BT, Parpieva N, Tillashaikhov M, Achar J
- Issue date: 2021 Jan
- Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.
- Authors: Yuen CM, Kurbatova EV, Tupasi T, Caoili JC, Van Der Walt M, Kvasnovsky C, Yagui M, Bayona J, Contreras C, Leimane V, Ershova J, Via LE, Kim H, Akksilp S, Kazennyy BY, Volchenkov GV, Jou R, Kliiman K, Demikhova OV, Vasilyeva IA, Dalton T, Cegielski JP
- Issue date: 2015 Dec